Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05379972 · ClinicalTrials.gov registry record · Phase 2

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

A Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, sponsored by University of Colorado, Denver.

Active
Registry status
Phase 2
Development phase
9
Enrollment target
4
Study locations

NCT05379972: Active Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, sponsored by University of Colorado, Denver.

NCT05379972 is a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 9 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05379972, a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
9 participants
Enrollment target
4
Study locations

Study Summary

This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.

Primary Outcome

The proportion of patients with a complete response or partial response to treatment according to Immune Response Evaluation Criteria in Solid Tumors (iRECIST 1.1)

Conditions Studied

Gastric Cancer GastroEsophageal Cancer

Interventions

  • DRUG Pembrolizumab
  • RADIATION Stereotactic Body Radiation Therapy
  • DRUG Olaparib

Study Locations (4)

Colorado

  • University of Colorado Health - Aurora
  • UCHealth Memorial Hospital Central - Colorado Springs
  • UCHealth Memorial Hospital North - Colorado Springs
  • UCHealth Highlands Ranch Hospital - Highlands Ranch

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2023-01-12
Est. Completion 2028-12
Phase Phase 2
University of Colorado, Denver

1,283 total trials

What the registry record for NCT05379972 still lists

NCT05379972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT05379972 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT05379972 about?

NCT05379972 is a clinical study titled "Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers". This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.

What is the current status of trial NCT05379972?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2023-01-12. Estimated completion is 2028-12.

What conditions does trial NCT05379972 study?

This clinical trial studies the following conditions: Gastric Cancer, GastroEsophageal Cancer.

What interventions are being tested in trial NCT05379972?

The interventions under investigation include: Pembrolizumab (DRUG), Stereotactic Body Radiation Therapy (RADIATION), Olaparib (DRUG).

Who is sponsoring clinical trial NCT05379972?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05379972 being conducted?

This trial has 4 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05379972's enrollment target sits among peer trials

9 153rd of 153 higher than 1 of 153 other Gastric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05379972, the US trial registry maintained by the National Library of Medicine. NCT05379972 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.